Evidence map›Paper›PMID 41481588›Full record

ArticlePLoS computational biology2026

DSCA-HLAII: A dual-stream cross-attention model for predicting peptide-HLA class II interaction and presentation.

Ke Yan, Hongjun Yu, Shutao Chen, Alexey K Shaytan, Bin Liu, Youyu Wang

Abstract read
In one paragraph

Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ke YanSchool of Computer Science and Technology, Beijing Institute of Technology, Beijing, China.
Hongjun YuSchool of Computer Science and Technology, Beijing Institute of Technology, Beijing, China.
Shutao ChenSchool of Computer Science and Technology, Beijing Institute of Technology, Beijing, China.
Alexey K ShaytanDepartment of Biology, Lomonosov Moscow State University, Moscow, Russia.
Bin LiuSchool of Computer Science and Technology, Beijing Institute of Technology, Beijing, China.ORCID https://orcid.org/0000-0001-6314-0762
Youyu WangDepartment of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationThe interaction between peptides and human leukocyte antigen class II (HLA-II) molecules plays a pivotal role in adaptive immune responses, as HLA-II mediates the recognition of exogenous antigens and initiates T cell activation through peptide presentation. Accurate prediction of peptide-HLA-II binding serves as a cornerstone for deciphering cellular immune responses, and is essential for guiding the optimization of antibody therapeutics. Researchers have developed several computational approaches to identify peptide-HLA-II interaction and presentation. However, most computational approaches exhibit inconsistent predictive performance, poor generalization ability and limited biological interpretability.

resultsIn this study, we present DSCA-HLAII, a novel predictive framework for peptide-HLA-II interactions and presentation based on a dual-stream cross-attention architecture. The framework proposes a dual-stream cross-attention (DSCA) mechanism to integrate pre-trained semantic embedding ESMC with sequence-level ONE-HOT features. The DSCA mechanism effectively models the interaction dynamics between peptides and HLA-II molecules, enabling the precise identification of key binding sites. Experimental results demonstrate that DSCA-HLAII consistently surpasses existing state-of-the-art approaches, demonstrating high accuracy and robustness in predicting peptide-HLA-II interactions and presentation. We further demonstrate the capability of DSCA-HLAII for predicting peptide binding cores and assessing antibody immunogenicity, which is expected to advance artificial intelligence-based peptide drug discovery.

Indexed as

Antigen PresentationComputational BiologyHistocompatibility Antigens Class IIPeptidesAlgorithmsBinding SitesHumansProtein BindingHistocompatibility Antigens Class IIPeptides

Identifiers

PMID41481588
PMCPMC12758783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.